Sign in
TLSI Stock Price, Chart, Stats & News
TriSalus Life Sciences, Inc.
Save
142.92M
Market cap
–
Current P/E
–
Forward P/E
TLSI chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 84.57% |
Operating margin | -59.68% |
Pretax margin | -86.86% |
Net margin | -86.88% |
Effective tax rate | 0.02% |
ROA | -111.03% |
ROE | 137.18% |
D/E | -1.02x |
Interest coverage ratio | -4.86x |
TLSI valuation
P/E | – |
P/S | 3.23x |
P/B | -5.33x |
P/CF | -10.01x |
P/FCF | -7.71x |
P/OCF | -10.01x |
PEG | -0.47x |
EV multiple | -4.71x |
About
TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers. The company's product portfolio includes the TriNav Infusion System, designed for hepatic arterial infusion to treat liver tumors, and the Pancreatic Retrograde Venous Infusion System, which addresses pancreatic tumors. Additionally, TriSalus is advancing SD-101, an investigational immunotherapeutic that incorporates pressure-enabled drug delivery technology.
Similar securities
Based on sector and market capitalization
Report issue